Anuurad Erdembileg, M.D., Ph.D., M.A.S.
Lipid and Lipoprotein Metabolism
- Assistant Dean for Research
- Director, School of Medicine Office of Research
Dr. Erdembileg's research interest is focused on risk factors for cardiovascular diseases, including metabolic syndrome, inflammation, genetics and lipid and lipoprotein metabolism in various ethnic/racial groups. Many of the results to date have focused on the characterization of a high-risk phenotype and have aimed to analyze synergistic, contributory effects of metabolic, genetic and inflammatory risk factors in promoting cardiovascular disease. I have specifically pursued models illustrating an association of genotypes with cardiovascular disease phenotypes.
For his full details on Dr. Erdembileg's leadership role and activities, please visit his executive leadership bio page.
Endocrinology, Diabetes, and Metabolism
M.D., Mongolian National Medical University, Ulaanbaatar Mongolia 1996
Ph.D., Shimane University School of Medicine, Izumo/Shimane Japan 2005
M.A.S., UC Davis, Davis CA 2009
Internship: Pediatrics, Mongolian National Medical University Hospital, Ulaanbaatar, Mongolia 1996
Mongolian Medical License, 1996
American Heart Association
Society for Clinical Translational Science
Honors and Awards
The California Clinical Nutrition Research Unit and the Richard C. Woodard Memorial Endowed Fund research award winner for best papers in nutrition, metabolism, and vascular disease., 2006
UC Davis Award for Excellence in Postdoctoral Research, 2007
Select Recent Publications
Enkhmaa B, Anuurad E, Zhang W, Abbuthalha A, and Berglund L. Genetics of lipoprotein(a) in relation to coronary heart disease. In: eLS. John Wiley & Sons, Ltd: Chichester. 2013; 1-15.
Enkhmaa B, Anuurad E, Zhang W, Berglund L. Significant associations between lipoprotein(a) and corrected apolipoprotein B-100 levels in African-Americans. Atherosclerosis. 2014; 235(1): 223-9.
Enkhmaa B, Anuurad E, Zhang W, Abbuthalha A, Li XD, Dotterweich W, Pollard RB, Asmuth DM, Berglund L. HIV disease activity as a modulator of lipoprotein(a) and allele-specific apolipoprotein(a) levels. Arterioscler Thromb Vasc Biol. 2013; 33(2): 387-92.
Gungor Z, Anuurad E, Enkhmaa B, Zhang W, Kim K, Berglund L. Apo E4 and lipoprotein-associated phospholipase A2 synergistically increase cardiovascular risk. Atherosclerosis. 2012; 223(1): 230-4.
Enkhmaa B, Anuurad E, Ozturk Z, Zhang W, Pearson TA, Berglund L. Differential associations of serum amyloid A and pentraxin-3 with allele-specific lipoprotein(a) levels in African Americans and Caucasians. Transl Res. 2011; 158(2): 92-8.
Enkhmaa B, Anuurad E, Zhang W, Tran T, Berglund L. Lipoprotein(a): genotype-phenotype relationship and impact on atherogenic risk. Metab Syndr Relat Disord. 2011; 9(6): 411-8.
Anuurad E, Enkhmaa B, Gungor Z, Zhang W, Tracy RP, Pearson TA, Kim K, Berglund L. Age as a modulator of inflammatory cardiovascular risk factors. Arterioscler Thromb Vasc Biol. 2011; 31(9): 2151-6.
Anuurad E, Enkhmaa B, Berglund L. Enigmatic role of lipoprotein(a) in cardiovascular disease. Clin Transl Sci. 2010; 3(6): 327-32.
Ozturk Z, Enkhmaa B, Shachter NS, Berglund L, Anuurad E. Integrated role of two apoliprotein E polymorphisms on apolipoprotein B levels and coronary artery disease in a biethnic population. Metab Syndr Relat Disord. 2010; 8(6): 531-8.
Enkhmaa B, Anuurad E, Zhang Z, Pearson TA, Berglund L. Usefulness of apolipoprotein B/apolipoprotein A-I ratio to predict coronary artery disease independent of the metabolic syndrome in African Americans. Am J Cardiol. 2010; 106(9): 1264-9.